Anebulo Pharmaceuticals, Inc. (ANEB) DCF Valuation

Anebulo Pharmaceuticals, Inc. (ANEB) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Anebulo Pharmaceuticals, Inc. (ANEB) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Streamline your analysis and improve precision with our (ANEB) DCF Calculator! With real data from Anebulo Pharmaceuticals and customizable assumptions, this tool empowers you to forecast, analyze, and value Anebulo like a seasoned investor.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -.2 -30.2 .0 -11.8 -8.1 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation 1.0 3.6 6.8 11.8 .3 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -1.2 -33.9 -6.8 -23.6 -8.3 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 3.0 20.0 14.5 11.2 3.1 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .0 .1 .4 .5 .2 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -1.2 -33.9 -6.8 -23.6 -8.3 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -.2 -30.1 .3 -11.6 -8.4 -.2 .0 .0 .0 .0
WACC, % 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39
PV UFCF
SUM PV UFCF -.1
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 0
Net Debt -3
Equity Value 3
Diluted Shares Outstanding, MM 26
Equity Value Per Share 0.11

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator with pre-filled real ANEB financials.
  • Real-World Data: Historical data and forward-looking estimates (as shown in the yellow cells).
  • Forecast Flexibility: Change forecast assumptions like revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly see the impact of your inputs on Anebulo Pharmaceuticals’ valuation.
  • Professional Tool: Built for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Structured for clarity and ease of use, with step-by-step instructions.

Key Features

  • Comprehensive Drug Development Tracker: Detailed timelines and milestones for Anebulo's pipeline projects.
  • Market Opportunity Analysis: Insights into the market landscape and potential revenue streams for ANEB.
  • Customizable Financial Projections: Adjust assumptions for R&D expenses, market penetration, and pricing strategies.
  • Integrated Risk Assessment Tools: Evaluate clinical trial risks and regulatory hurdles specific to Anebulo Pharmaceuticals.
  • User-Friendly Dashboard: Visual representations of key performance indicators and strategic metrics for ANEB.

How It Works

  • 1. Access the Model: Download and open the Excel template containing Anebulo Pharmaceuticals, Inc.'s (ANEB) preloaded data.
  • 2. Adjust Key Variables: Modify essential inputs such as projected growth rates, discount rates, and research expenditures.
  • 3. Analyze Results in Real-Time: The DCF model automatically computes the intrinsic value and net present value (NPV).
  • 4. Explore Different Scenarios: Evaluate various forecasts to understand a range of valuation possibilities.
  • 5. Present with Assurance: Deliver expert valuation analysis to enhance your strategic decision-making.

Why Choose This Calculator for Anebulo Pharmaceuticals, Inc. (ANEB)?

  • Designed for Industry Experts: A specialized tool tailored for researchers, financial analysts, and investors.
  • Comprehensive Data: Anebulo’s historical and projected financials integrated for precise analysis.
  • Flexible Scenario Analysis: Effortlessly explore various forecasts and assumptions.
  • Insightful Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
  • User-Friendly Interface: Clear, step-by-step guidance to facilitate your calculations.

Who Should Use This Product?

  • Investors: Accurately assess Anebulo Pharmaceuticals’ fair value prior to making investment choices.
  • CFOs: Utilize a high-quality DCF model for financial reporting and analysis.
  • Consultants: Effortlessly customize the template for client valuation reports.
  • Entrepreneurs: Acquire insights into financial modeling practices employed by leading pharmaceutical companies.
  • Educators: Implement it as a teaching resource to illustrate valuation techniques.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Anebulo Pharmaceuticals historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Anebulo Pharmaceuticals, Inc. (ANEB).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.